1) DEFINITION;

2) PREVALENCE OF ATRIAL FIBRILLATION;

3) PREVALENCE OF ATRIAL AMYLOIDOSIS IN PATIENTS WITH LONG-STANDING ATRIAL FIBRILLATION AND RHEUMATIC HEART DISEASE.

4) ATRIAL FIBRILLATION WITH STRUCTURALLY NORMAL HEARTS: LONE AND PSEUDO LONE ATRIAL FIBRILLATION;

5) GENETIC MUTATIONS AND ATRIAL FIBRILLATION: IS FAMILIAL ATRIAL FIBRILLATION A GENETICALLY HETEROGENEOUS DISORDER? ;

6) THE POSSIBLE CARDIAC ETIOLOGIES OF ATRIAL FIBRILLATION;

7) THE POSSIBLE EXTRA-CARDIAC ETIOLOGIES OF ATRIAL FIBRILLATION;

8) THE ATRIAL FIBRILLATION IN CONGENITAL HEART DISEASE;

9) THE ELECTROPHYSIOLOGICAL MECHANISM OF ATRIAL FIBRILLATION. THE CONCEPT OF ATRIAL REMODELING OF WIJFFELS AND ALESSIE (1995);

10) BASIC MECHANISMS OF ATRIAL FIBRILLATION--VERY NEW INSIGHTS INTO VERY OLD IDEAS;

11) ELECTROPHYSIOLOGICAL PROPERTIES OF THE HUMAN ATRIUM IN ATRIAL FIBRILLATION;

12) PAROXYSMAL ATRIAL FIBRILLATION: EPIDEMIOLOGY, PATHOPHYSIOLOGY, CLINICAL ASPECTS;

13) TRANSIENT ATRIAL FIBRILLATION INDUCED BY ADENOSINE. POSIBLE MECHANISMS.

14) IS INFLAMMATION A CAUSATIVE AGENT OF PAROXYMAL ATRIAL FIBRILLATION? VALUE OF MARKER OF INFLAMMATION AS HIGH-SENSITIVITY C-REACTIVE PROTEIN (HS-CRP), INTERLEUKIN-6 (IL-6), AND TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) BEFORE AND AFTER PHARMACOLOGICAL CARDIOVERSION IN PATIENTS WITH PAROXYSMAL ATRIAL FIBRILLATION;

15) CAN HOLTER MONITORING IDENTIFY OCCULT PAROXYSMAL ATRIAL FIBRILLATION IN THE DIAGNOSIS OF STROKE MECHANISM;

16) ROLE OF MUSCARINIC SUBTYPE-2 (M2-MUSCARINIC) ACETYLCHOLINE RECEPTOR AUTOANTIBODIES (M2-AAB) IN MEDIATING THE DEVELOPMENT OF ATRIAL FIBRILLATION IN PATIENTS WITH DILATED CARDIOMYOPATHY. MUSCARINIC SUBTYPE-2 RECEPTOR AUTOANTIBODIES: ACTORS OR BYSTANDERS IN HUMAN ATRIAL FIBRILLATION?

17) SUSTAINED OR PERSISTENT NON-RHEUMATIC (NON-VALVULAR) ATRIAL FIBRILLATION: CHANGES IN EXERCISE CAPACITY, ECHOCARDIOGRAPHIC FINDINGS AND PLASMA ATRIAL NATRIURETIC PEPTIDE (ANP) CONCENTRATIONS;

18) REENTRY IN A PULMONARY VEIN (LOCAL REENTRY IN THE VEIN) AS A POSSIBLE MECHANISM OF FOCAL ATRIAL FIBRILLATION;

19) THE DIFFERENTIAL DIAGNOSIS OF ATRIAL FIBRILLATION;

20) THE PROGNOSIS IN ATRIAL FIBRILLATION;

21) ATRIAL FIBRILLATION. A TACHYCARDIA-INDUCED ATRIAL CARDIOMYOPATHY.

22) ATRIAL FIBRILLATION IN HEART FAILURE: EPIDEMIOLOGY, PATHOPHYSIOLOGY, AND RATIONALE FOR THERAPY;

23) ASSOCIATION BETWEEN OBSTRUCTIVE SLEEP APNEA AND ATRIAL FIBRILLATION;

24) THE PREDICTION OF ATRIAL FIBRILLATION RECURRENCE AFTER ELECTRICAL CARDIOVERSION WITH P WAVE SIGNAL AVERAGED ELECTROCARDIOGRAM.

25) VALUE OF TRANSESOPHAGEAL ECOCARDIOGRAPHY IN ATRIAL FIBRILLATION;

26) VALUE OF MAXIMUM P-WAVE DURATION AND P-WAVE DISPERSION PREDICT RECURRENCE OF PAROXYSMAL ATRIAL FIBRILLATION IN PATIENTS WITH WOLFF-PARKINSON-WHITE SYNDROME AFTER SUCCESSFUL RADIOFREQUENCY CATHETER ABLATION;

27) BEAT-TO-BEAT QT INTERVAL VARIABILITY IN ATRIAL FIBRILLATION WITH AND WITHOUT CONGESTIVE CARDIAC FAILURE;

28) AUTONOMIC TONE FLUCTUATIONS MEASURED BY HEART RATE VARIABILITY (HRV) PRECEDE EPISODES OF PAROXYSMAL ATRIAL FIBRILLATION?

29) ASSOCIATION OF ANTI-HEAT SHOCK PROTEIN 65 ANTIBODIES WITH DEVELOPMENT OF POSTOPERATIVE ATRIAL FIBRILLATION: ARE AUTOIMMUNE AND INFLAMMATORY RESPONSES AGAINST HEAT SHOCK PROTEIN 65 (HSP65) INVOLVED IN OF POSTOPERATIVE ATRIAL FIBRILLATION?;

30) THE -174G/C INTERLEUKIN-6 POLYMORPHISM INFLUENCES POSTOPERATIVE INTERLEUKIN-6 LEVELS AND POSTOPERATIVE ATRIAL FIBRILLATION. IS ATRIAL FIBRILLATION AN INFLAMMATORY COMPLICATION?

31) THE VENOUS PLASMA LEVELS OF SOLUBLE P-SELECTIN (A MARKER OF PLATELET ACTIVATION) IN PATIENTS WITH MODERATE-TO-SEVERE MITRAL STENOSIS AND ATRIAL FIBRILLATION;

32) VALUE OF ENDOSCOPY FROM 3D MRA IMAGES (MRA-VE) OR MAGNETIC RESONANCE ANGIOGRAPHY VIRTUAL ENDOSCOPY IN THE ASSESSMENT OF PULMONARY VEINS BEFORE RADIOFREQUENCY ABLATION PROCEDURES FOR ATRIAL FIBRILLATION;

33) ATRIAL FIBRILLATION AND TROPONIN I LEVELS WITHOUT CORONARY ATHEROSCLEROSIS;

34) PHARMACOLOGICAL APPROACH FOR THE PREVENTION OF ATRIAL FIBRILLATION AFTER CARDIOVASCULAR SURGERY: PERIOPERATIVE BETA-BLOCKERS, AMIODARONE, AND ATRIAL PACING.

35) RATE VERSUS RHYTHM CONTROL IN ATRIAL FIBRILLATION.RATE CONTROL WITH LONG-TERM ANTICOAGULATION IN ATRIAL FIBRILLATION;

36) THE THERAPEUTIC APPROACH TO PAROXYSMAL OR PERSISTENT ATRIAL FIBRILLATION: RHYTHM CONTROL VERSUS RATE CONTROL;

37) THE GENETIC CALCIUM CHANNEL BLOCKER IN RATE CONTROL OF ATRIAL FIBRILLATION ADENOVIRUS-MEDIATED DELIVERY OF GEM MARKEDLY DECREASED L-TYPE CALCIUM CURRENT DENSITY IN VENTRICULAR MYOCYTES;

38) PHARMACOLOGIC METHODS OF ADEQUATE RATE CONTROL IN ATRIAL FIBRILLATION: BETA-BLOCKERS, DIGOXIN ALONE; BETA-BLOCKER AND DIGOXIN OR A CALCIUM CHANNEL BLOCKER AND DIGOXIN? (THE AFFIRM STUDY);

39) NEW DRUGS IBUTILIDE, DOFETILIDE AND AZIMILIDE (ALIVE) IN PHARMACOLOGIC CARDIOVERSION OF ATRIAL FIBRILLATION;

40) AMIODARONE IN PHARMACOLOGIC CARDIOVERSION OF ATRIAL FIBRILLATION;

41) SOTALOL IN PHARMACOLOGIC CARDIOVERSION OF ATRIAL FIBRILLATION;

42) EFFICACY OF INTRAVENOUSLY ADMINISTERED TEDISAMIL (A PREDOMINANT CLASS III DRUG.) FOR RAPID CONVERSION OF RECENT-ONSET ATRIAL FIBRILLATION OR ATRIAL FLUTTER;

43) HIGH DOSE MAGNESIUM SUPPLEMENTATION TO PREVENT ATRIAL FIBRILLATION AFTER OFF PUMP CABG;

44) THE USE OF WARFARIN AGENT IN ATRIAL FIBRILLATION;

45) CONTRAINDICATIONS OF WARFARIN.

46) RISK FACTORS FOR STROKE AND THROMBOPROPHYLAXIS IN ATRIAL FIBRILLATION;

47) DOES COMBINING ASPIRIN AND ADJUSTED-DOSE WARFARIN DECREASE THE RISK OF STROKE FOR PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION?

48) SHOULD ASPIRIN BE CONTINUED IN PATIENTS STARTED ON WARFARIN FOR MECHANICAL HEART VALVE PATIENTS, AND FOR OTHER ROUTINE WARFARIN INDICATIONS? ARE THERE ADEQUATE DATA TO GUIDE THIS COMMON CLINICAL DECISION.

49) XIMELAGATRAN: A NOVEL ORAL DIRECT THROMBIN INHIBITOR FOR LONG-TERM ANTICOAGULATION. REPLACE WARFARIN?

50) LOW-MOLECULAR-WEIGHT HEPARIN AS BRIDGING ANTICOAGULATION DURING INTERRUPTION OF WARFARIN: ASSESSMENT OF A STANDARDIZED PERIPROCEDURAL ANTICOAGULATION REGIMEN: SUBCUTANEOUS DALTEPARIN SODIUM, 100 IU/KG TWICE DAILY, STARTING 3 DAYS BEFORE THE PROCEDURE.

51) MODERN ASPECTS OF ANTITHROMBOTIC TREATMENT IN ATRIAL FIBRILLATION;

52) EFFICACY OF PROPAFENONE FOR MAINTAINING SINUS RHYTHM IN PATIENTS WITH RECENT ONSET OR PERSISTENT ATRIAL FIBRILLATION AFTER CONVERSION;

53) METOPROLOL PROPHYLAXIS AGAINST POSTOPERATIVE ATRIAL FIBRILLATION;

54) OVERVIEW OF NEW AGENTS, THEIR MECHANISMS OF ACTION AND POTENTIAL CLINICAL UTILITY IN ATRIAL FIBRILLATION;

55) ANGIOTENSIN II TYPE 1 RECEPTOR ANTAGONIST ON ELECTRICAL AND STRUCTURAL REMODELING IN ATRIAL FIBRILLATION. THE USE OF ACE INHIBITOR OR ANGIOTENSIN II ANTAGONIST IN THE TREATMENT OF STRUCTURAL ATRIAL FIBRILLATION;

NON-PHARMACOLOGICAL APPROACH

56) TRANSTHORACIC CARDIOVERSION IN PATIENTS WITH ATRIAL FIBRILLATION: COMPARISON OF THREE DIFFERENT WAVEFORMS: MONOPHASIC; RECTILINEAR BIPHASIC WAVEFORM AND BIPHASIC TRUNCATED WAVEFORM;

57) IMMEDIATE AND SHORT-TERM COMPLICATIONS (RELATED TO PROCEDURAL SEDATION AND ANALGESIA AND ATTRIBUTED TO ELECTRICAL CARDIOVERSION) OF TRANSTHORACIC CARDIOVERSION IN PATIENTS WITH ATRIAL FIBRILLATION;

58) SHOULD BE USED EXTERNAL ELECTRICAL CARDIOVERSION FOR TERMINATION OF ATRIAL FIBRILLATION IN PATIENTS WITH PERMANENT PACING SYSTEMS?

59) PALLIATIVE APPROACH: PACING THERAPY OR ATRIOVENTRICULAR NODE ABLATION IN ATRIAL FIBRILLATION: ATRIOVENTRICULAR NODAL ABLATION AND PACEMAKER IMPLANTATION (ABLATE AND PACE);

60) THE ROLE OF SLOW-PATHWAY MODIFICATION IN ATRIAL FIBRILLATION;

61) MULTISITE ATRIAL PACING INDICATIONS: 1) SIMULTANEOUS BIATRIAL STIMULATION WITH THE LEADS PLACED IN THE RIGHT APPENDAGE AND IN THE LEFT ATRIUM THROUGH THE CORONARY SINUS; 2) DUAL SITE RIGHT ATRIAL PACING WITH THE LEADS POSITIONED IN THE ROOF OF THE RIGHT ATRIUM AND PROXIMAL TO THE OSTIUM OF THE CORONARY SINUS;

62) SINGLE SITE NON-CONVENTIONAL ATRIAL PACING WITH THE LEAD PLACED AT THE LEVEL OF THE INTERATRIAL SEPTUM, IN THE TRIANGLE OF KOCH, IN ORDER TO MODULATE THE ANISOTROPIC CONDUCTION OF THIS ZONE, RESPONSIBLE FOR THE ONSET OF ATRIAL FIBRILLATION;

63) DUAL-CHAMBER DEFIBRILLATOR EQUIPPED WITH PAINLESS ANTITACHY PACING THERAPIES AND ATRIAL CARDIOVERSION FOR ATRIAL FIBRILLATION. THE ROLE OF PACEMAKER AND DEFIBRILLATOR THERAPY FOR THE TREATMENT OF ATRIAL FIBRILLATION. THE CURRENT APPLICATION OF DEVICE THERAPY AND HOW THE ALGORITHMS WORK;

64) PERCUTANEOUS CATHETER ABLATION INDICATIONS FOR ATRIAL FIBRILLATION;

65) PULMONARY VEIN ISOLATION IN PATIENTS WITH SICK SINUS SYNDROME AND ATRIAL FIBRILLATION;

66) PULMONARY VEIN ISOLATION DURING ATRIAL FIBRILLATION USING A CIRCUMFERENTIAL CRYOABLATION CATHETER;

67) CATHETER ABLATION PROCEDURES FOR THE MAINTENANCE OF SINUS RHYTHM IN PATIENTS WITH ATRIAL FIBRILLATION: ARE CURES REALLY ACHIEVED? IS NECESSARY RANDOMIZED CONTROLLED TO CONFIRM POSTULATED LONG-TERM CURE RATES FOR ATRIAL FIBRILLATION?

“PACHÓN’S PROCEDURE”

68) "NEW HORIZONS IN THE PHYSIOPATHOLOGY AND CURATIVE CATHETER-ABLATION TREATMENT OF ATRIAL FIBRILLATION AND FUNCTIONAL BRADYCARDIAS"

69) "ATRIAL FIBRILLATION NESTS" - A NEW AF PHYSIOPATHOLOGY BASED ON THE ATRIAL FIBRILLATION CELL.

70) ARE THE REENTRY AND/OR AUTOMATISM THE REAL ELECTROPHYSIOLOGIC AF MECHANISM?;

71) A NEW CURATIVE ATRIAL FIBRILLATION TREATMENT USING THE CATHETER RF-ABLATION GUIDED BY ENDOCARDIAL FOURIER-RIGHT-SHIFT;

72) A NEW CURATIVE ATRIAL FIBRILLATION TREATMENT USING THE CATHETER RF-ABLATION OF "RESONANT AREAS" DURING ATRIAL FIBRILLATION;

73) A NEW CONCEPT FOR MAINTENANCE AND ESPONTANEOUS UNEXPECTEDLY REVERSION OF ATRIAL FIBRILLATION.

74) CURING THE ATRIAL FIBRILLATION NORMAL HEART ASSOCIATED BRADYCARDIA BY CATHETER RF ABLATION WITHOUT DRUGS OR PACEMAKER;

75) A NEW TREATMENTO OF THE NEUROCARDIOGENIC SYNCOPE, FUNCTIONAL AV-BLOCK AND SINUS DYSFUNCTION BY CATHETER RF-ABLATION.

76) THE COX MAZE III PROCEDURE FOR THE TREATMENT OF ATRIAL FIBRILLATION SURGICAL MAZE OPERATION INDICATIONS;

77) MINIMALLY INVASIVE MAZE OR MINI-MAZE PROCEDURE;

78) MINIMALLY INVASIVE MAZE OR MINI-MAZE PROCEDURE ASSOCIATED WITH PROPHYLACTIC IMPLANTATION OF BIVENTRICULAR PACEMAKERS IN PATIENTS WITH LEFT BUNDLE BRANCH BLOCK;

79) OTHERS NONINCISIONAL CHIRURGICAL TECHNIQUES PROCEDURES: CRYOABLATION; RADIOFREQUENCY, MICROWAVE, LASER, SURGICAL ROBOTS, AND FOCUSED ULTRASOUND ENERGY;

80) CONCOMITANT ANTI-ARRHYTHMIC SURGERY, USING IRRIGATED COOLED-TIP RADIOFREQUENCY ABLATION, TO TREAT PERMANENT ATRIAL FIBRILLATION IN CABG PATIENTS (CORONARY ARTERY BYPASS GRAFTING);

81) MINIMALLY INVASIVE SURGICAL AF ABLATION IN PATIENTS WITH ISOLATED AF;

MISCELLANEOUS TOPIC

82) HYBRID THERAPY OF ATRIAL FIBRILLATION.

83) ATRIAL FIBRILLATION IN THE ELDERLY: FACTS AND MANAGEMENT.

84) ATRIAL FIBRILLATION IN ATHLETE HEART.

85) ATRIAL FIBRILLATION AND PROMINENT J (OSBORN) WAVES IN CRITICAL HYPOTHERMIA;

86) THE "ASHMAN PHENOMENON," IN ATRIAL FIBRILLATION. THE DIFFERENTIAL DIAGNOSIS WITH VENTRICULAR ECTOPY;

87) OPERATIVE FACTORS THAT CONTRIBUTE TO POST-OPERATIVE ATRIAL FIBRILLATION.